| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LLY | Common Stock | Sale | $4,242,976 | -4,836 | -0.01% | $877.37 | 96,641,696 | 19 Feb 2025 | Direct | F1 |
| transaction | LLY | Common Stock | Sale | $1,288,771 | -1,467 | -0% | $878.51 | 96,640,229 | 19 Feb 2025 | Direct | F2 |
| transaction | LLY | Common Stock | Sale | $2,101,126 | -2,389 | -0% | $879.50 | 96,637,840 | 19 Feb 2025 | Direct | F3 |
| transaction | LLY | Common Stock | Sale | $1,138,413 | -1,293 | -0% | $880.44 | 96,636,547 | 19 Feb 2025 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $877.00 to $877.9956, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), and (4) to this Form 4. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $878.0318 to $879.0134, inclusive. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $879.0356 to $880.0154, inclusive. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $880.0494 to $880.88, inclusive. |